Prosecution Insights
Last updated: May 29, 2026

Insilico Medicine Ip Limited

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
3
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
2
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)Due ≤ 60 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (60%)
0
Easy (0%)
2
Unknown (40%)

Rejection Statute Mix

BucketCases
§103 only2 (40%)
§102 only1 (20%)
No statute on record2 (40%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
80% of docket
1
Information Tech
20% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ANDERSON, REBECCA L 1 73.2% +24.0%
HAVLIN, ROBERT H 1 52.3% +27.2%
SKIBINSKY, ANNA 1 38.8% +29.2%
BRACERO, ANDREW ANGEL 1 100.0% +0.0%
KALLAL, ROBERT JAMES 1 58.1% +37.7%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17800129 ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS BRACERO, ANDREW ANGEL 33d

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18049757 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS HAVLIN, ROBERT H 142d overdue
17596888 SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES KALLAL, ROBERT JAMES 25d overdue
17911376 RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY SKIBINSKY, ANNA 21d
18486369 LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF ANDERSON, REBECCA L 43d

Top Art Units

Art UnitApps
1626 2
1635 1
2126 1
1685 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18486369 LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF ANDERSON, REBECCA L 1626 §102 Non-Final OA 43d Pending Oct 13, 2023
18049757 SARS-COV-2 INHIBITORS HAVING COVALENT MODIFICATIONS FOR TREATING CORONAVIRUS INFECTIONS HAVLIN, ROBERT H 1626 Other Final Rejection 142d overdue Pending Oct 26, 2022
17911376 RETROSYNTHESIS-RELATED SYNTHETIC ACCESSIBILITY SKIBINSKY, ANNA 1635 §103 Non-Final OA 21d Pending Sep 13, 2022
17800129 ADVERSARIAL AUTOENCODER ARCHITECTURE FOR METHODS OF GRAPH TO SEQUENCE MODELS BRACERO, ANDREW ANGEL 2126 §103 Final Rejection 33d Pending Aug 16, 2022
17596888 SYNTHETIC BIOLOGICAL CHARACTERISTIC GENERATOR BASED ON REAL BIOLOGICAL DATA SIGNATURES KALLAL, ROBERT JAMES 1685 Other Non-Final OA 25d overdue Pending Dec 20, 2021

Managing Insilico Medicine Ip Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month